Review Article
A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan
| Study ID | Loc | Diagnosis | IBS-C | of total patients | Age () | of females | Intervention | Trial stage | Ref no. | MA |
| Fukudo 2019 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Not included | 181 | | 82.3% | Linaclotide 0.5 mg | III | 7 | Included | Fukudo 2018 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Not included | 382 | | 83.2% | Linaclotide 0.0625 mg Linaclotide 0.125 mg Linaclotide 0.25 mg Linaclotide 0.5 mg | II | 8 | Included | Kumagai 2018 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Included | 58 | | Not reported | Elobixibat 2.5 mg Elobixibat 5 mg Elobixibat 10 mg Elobixibat 15 mg Elobixibat 20 mg | I | 9 | Included | Nakajima 2018a | Japan | Rome III diagnostic criteria for functional constipation | Included | 132 | | 82.6% | Elobixibat 10 mg | III | 10 | Included | Nakajima 2018b | Japan | Rome III diagnostic criteria for functional constipation | Included | 163 | | 87.7% | Elobixibat 5 mg Elobixibat 10 mg Elobixibat 15 mg | II | 11 | Included | Fukudo 2015 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Included | 124 | | 87.9% | Lubiprostone 48 mg | III | 6 | Included | Fukudo 2011 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Included | 170 | | 90.6% | Lubiprostone 16 μg Lubiprostone 32 μg Lubiprostone 48 μg | II | 5 | Included | Mori 2019 | Japan | Rome IV diagnostic criteria for functional constipation | Included | 33 | | 100.0% | Magnesium oxide | — | 21 | | Nakajima 2019 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Included | 156 | | 85.6% | Polyethylene glycol 3350 plus electrolytes | III | 17 | | Kasugai 2019 | Japan | <3 SBMs per week, Rome III diagnostic criteria for functional constipation | Included | 250 | | 84.0% | Lactulose 13 g/day Lactulose 26 g/day Lactulose 39 g/day | II | 12 | Included |
|
|
IBS-C: irritable bowel syndrome with constipation; Loc: location; MA: meta-analysis; : number; : proportion; Ref no.: reference number; SBM: spontaneous bowel movement. |